Maravai LifeSciences/$MRVI
1D1W1MYTD1Y5YMAX
Capital at risk
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
- Ticker
- $MRVI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 415
- Headquarters
- San Diego, United States
- Website
- www.maravai.com
MRVI Metrics
BasicAdvanced
$996M
-
-$0.53
0.58
-
Price and volume
Market cap
$996M
Beta
0.58
52-week high
$9.42
52-week low
$2.55
Average daily volume
3.9M
Financial strength
Current ratio
4.052
Quick ratio
2.635
Long term debt to equity
0.583
Total debt to equity
0.854
Interest coverage (TTM)
-2.82%
Profitability
EBITDA (TTM)
-19.745
Gross margin (TTM)
35.71%
Net profit margin (TTM)
-37.07%
Operating margin (TTM)
-32.32%
Effective tax rate (TTM)
0.30%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-5.71%
Return on equity (TTM)
-33.05%
Valuation
Price to revenue (TTM)
4.677
Price to book
4.86
Price to tangible book (TTM)
-15.75
Price to free cash flow (TTM)
-27.24
Free cash flow yield (TTM)
-3.67%
Free cash flow per share (TTM)
-0.245
Growth
Revenue change (TTM)
-5.03%
Earnings per share change (TTM)
-60.70%
3-year revenue growth (CAGR)
-27.33%
3-year earnings per share growth (CAGR)
-2.59%
What the Analysts think about MRVI
Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.
Analyst projections of the future price of Maravai LifeSciences stock.
Bulls say / Bears say
Maravai reported Q4 2025 revenue of $49.9 million, beating the IBES estimate of $49.0 million, and delivered a positive adjusted EBITDA of $0.5 million versus a forecasted loss of $4.02 million, while issuing full-year 2026 guidance of $200–210 million in revenue and $18–20 million in EBITDA. (Reuters)
TriLink, Maravai LifeSciences’ nucleic acid segment, inaugurated a GMP enzyme manufacturing facility in Jupiter, Florida in June 2026—shipping its first commercial GMP enzyme batch—strengthening its integrated mRNA production supply chain. (Reuters)
The company refinanced its credit agreement on June 2, 2026, replacing roughly $242.9 million of existing debt with a $150 million term loan and a $30 million revolving facility, reducing total principal by $92.9 million and extending maturities to 2032 to enhance liquidity. (Business Wire)
Cygnus segment revenue was only $18.4 million in Q1 2026 versus $18.1 million a year earlier, reflecting a negligible 1.4% annual increase and limited diversification beyond TriLink. (SEC Filing)
Maravai recorded a net loss of $6.4 million in Q1 2026 despite positive EBITDA, underscoring ongoing non-operating expense pressures. (SEC Filing)
At March 31, 2026, the company had $242.9 million of outstanding term loan borrowings and incurred $5.7 million of interest expense in Q1, highlighting substantial leverage and fixed financing costs. (SEC Filing)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
MRVI Financial Performance
Revenues and expenses
MRVI Earnings Performance
Company profitability
Upcoming events
No upcoming events
MRVI News
AllArticlesVideos
Maravai LifeSciences Q2 Earnings Call Highlights
MarketBeat1 month ago
TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology
Business Wire2 months ago
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
Business Wire3 months ago
Funds containing MRVI
AllUSDEURGBP
Fund name | Fund size | $MRVI weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.10% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.10% |
iShares Healthcare Innovation£DRDR | £1B | 0.10% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.